The largest single stake in the firm is held by
the Swedish investment company Investor AB, controlled by the Wallenberg family, which holds 10.48.
The publication in the journal Science Translational Medicine
builds on several years' research at Sahlgrenska Academy and Wallenberg Centre for Molecular and Translational Medicine,
University of Gothenburg, and the Faculty of Medicine at Lund University.